Two of the most prevalent and dangerous of these drug-resistant bacteria are Methicillin-Resistant S. aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE). Testing was performed with the Zylast Antiseptic against both of these deadly bacteria. Not only did the Antiseptic destroy more than 99.99% of these bacteria on contact, it was still killing more than 90% of both VRE and MRSA one hour after it was applied.
All Zylast products have been shown to be persistent for six hours, and now have demonstrated rapid, broad-spectrum kill as well. In-vitro testing on skin substitutes has shown that all Zylast products are still killing at or above 97% of disease-causing bacteria at 1 hour, and remaining above 90% at 4 hours after application.
When the Zylast Antiseptic was tested, it was shown to be more than 100 times more effective against Norovirus than alcohol alone (Liu et al, BioScience Results). Previous testing has also been performed against the H1N1 flu, where the Zylast(R) Antiseptic killed 99.99% of the virus within 15 seconds.
Innovative BioDefense Inc, the creators of Zylast, believe the combination of increased immediate kill and long-lasting persistence can significantly reduce infection rates in hospitals, nursing homes, schools, and businesses. The Zylast products were 100 times more effective than necessary to exceed the FDA Healthcare Personnel Handwash requirement, and passed the Surgical Scrub test as well.
Studies have shown that even in hospitals, healthcare workers only comply with hand hygiene protocols about 50% of the time, leaving patients vulnerable nearly half the time.
Time-kill testing is specified by the FDA, and is a laboratory test designed to determine how well, and how long, a given product eliminates bacteria. A known amount of the bacteria is put into a solution of the antimicrobial product and left for the specified time -15, 30, or 60 seconds – and then counted to determine how effective the agent was in destroying the microbe. The testing was performed by one of the foremost independent microbiology labs in the country, BioScience Laboratories.
This combination of rapid, broad-spectrum kill and persistence has significant clinical importance. Using a product with persistence was shown to decrease illness-related absenteeism in elementary schools by 42% (Dyer et al), as compared to 0-19% with alcohol alone. In a pilot hospital study of more than 6,000 patients, hospital-acquired infection rates were reduced by 44% across 3 different wards using the Antiseptic.
The organisms tested:
Zylast(TM) is a developer, manufacturer and marketer of a full line ofantisepticproducts for use by healthcare professionals, businesses and consumers.Zylast products, based on proprietary and patented combinations of pharmaceutical ingredients, are owned by Innovative BioDefense Inc, a privately held company headquartered in Lake Forest, CA.
SOURCE Innovative BioDefense Inc